BioAge Labs, Inc. Common Stock (BIOA) Stock Price

BIOAStock
$9.65+101.04%52W
Market Cap$442.91M
P/E
PEG Ratio
Div yield
Beta2.23

BIOA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-67.17%
Price vs S&P 500 (4W)-12.02%
VGM Score57.62

BIOA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.62-$0.58+7.09%(+$0.04)
Q1 2026-$0.63-$0.52+17.13%(+$0.11)
Q4 2025-$0.67-$0.72-7.69%(-$0.05)
Q3 2025-$0.51-$0.56-9.02%(-$0.05)
Q2 2025-$0.38-$0.60-57.31%(-$0.22)

BIOA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.15
4.20
4.20
4.20

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
BIOABioAge Labs, Inc. Common Stock
CAC$9.65
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About BioAge Labs, Inc. Common Stock

Bioage Labs is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases like obesity by targeting the biology of aging. Its pipeline includes NLRP3 inhibitors and APJ agonists designed to address the underlying mechanisms of age-related metabolic dysfunction.